Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of LEXX is 4.5 and suggests 466% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
Buy
Sell